New Director Sales and Business Development for GEA Pharma Systems in Latin America
6 January 2012 | By The Words Workshop Ltd
GEA Pharma Systems has appointed Zósimo López Moreno...
List view / Grid view
News
FDA approves Merck’s ISENTRESS® (raltegravir)
6 January 2012 | By Merck
The U.S. FDA recently approved the use of ISENTRESS® (raltegravir) in combination with other antiretroviral (ARV) medicines...
Gilead Sciences announces early termination of Hart-Scott-Rodino waiting period
6 January 2012 | By Gilead Sciences
Gilead Sciences, Inc. has received early termination of the required waiting period...
Merck Millipore collaborates with Peking University
5 January 2012 | By Merck Millipore
Merck Millipore, announced that the division was invited to serve on the faculty of the CPIER at Peking University...
Biogen Idec and Isis Pharmaceuticals announce global collaboration
4 January 2012 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into an exclusive, worldwide option and collaboration agreement...
Tivozanib demonstrated superiority over sorafenib in patients with advanced renal cell cancer in Phase 3 TIVO-1 trial
4 January 2012 | By Astellas
Tivozanib has demonstrated superiority over sorafenib...
Advanced magnetic resonance imaging technology suggests axonal repair in MS patients treated with COPAXONE®
3 January 2012 | By Teva
Study findings published in Frontiers in Bioscience...
Onfi™ (clobazam) tablets now available in the US at retail pharmacies
3 January 2012 | By H. Lundbeck A/S
Lundbeck announced that Onfi tablets are now available for prescribing in the United States...
Teva announces management succession
1 January 2012 | By Teva
Dr. Jeremy Levin, a former Senior Executive at Bristol-Myers Squibb, to succeed Shlomo Yanai as President and CEO...
Pfizer receives FDA approval to extend use of Prevnar 13®
30 December 2011 | By Pfizer
First pneumococcal conjugate vaccine for adults 50+ has potential to help address high incidence of pneumococcal pneumonia...
FDA to review potential new use of XGEVA® (Denosumab) at ODAC meeting
29 December 2011 | By Amgen
FDA has invited Amgen to participate in a meeting of the ODAC on Feb. 8, 2012 to discuss the sBLA for XGEVA® (denosumab)...
Janssen Research & Development submits application to U.S. FDA for XARELTO® (rivaroxaban) to reduce secondary cardiovascular events in patients with ACS
29 December 2011 | By Janssen Research & Development, LLC
Janssen Research & Development, LLC (JRD) have announced that it has submitted a sNDA to the FDA seeking approval for the use of XARELTO® (rivaroxaban)...
ICON announces Dr. Anthony Murphy to retire from Board of Directors
27 December 2011 | By ICON plc
ICON plc., has announced the retirement of Non-Executive Director, Dr. Anthony Murphy to become effective on 31st December 2011...
Bayer’s Xarelto® approved in the EU for the prevention of stroke in patients
20 December 2011 | By Bayer HealthCare
The only new oral anticoagulant approved in three indications across all 27 EU member states...
Alkermes initiates phase 3 clinical study of ALKS 9070 for treatment of schizophrenia
20 December 2011 | By Alkermes
ALKS 9070 is designed to offer once-monthly version of Aripiprazole...
